Efficacy of vedolizumab as maintenance therapy in a patient with ulcerative colitis receiving haemodialysis in end-stage kidney failure: A case report

Efficacy of vedolizumab as maintenance therapy in a patient with ulcerative colitis receiving haemodialysis in end-stage kidney failure: A case report

This report describes vedolizumab’s clinical efficacy and safety in a patient with severe ulcerative colitis on haemodialysis for an end-stage kidney failure. The patient was a 75-year-old man on long-standing chronic diffusive three times per week haemodialytic treatment due to vascular nephropathy...

Full description

Bibliographic Details
Main Authors:	Guglielmo Albertini Petroni, Laura Francesca Pisani, Edoardo Borsotti, Maria Doria, Maria Laura Annunziata
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-04-01
Series:	SAGE Open Medical Case Reports
Online Access:	https://doi.org/10.1177/2050313X231165641

Similar Items

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
by: Renato Sablich, et al.
Published: (2023-02-01)

Patient considerations in the management of ulcerative colitis – role of vedolizumab
by: Kothari M, et al.
Published: (2015-08-01)

Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis
by: Maria Gonzalez-Vivo, et al.
Published: (2022-06-01)

Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?
by: Gilroy L, et al.
Published: (2014-05-01)

The role of vedolizumab in patients with moderate-to-severe Crohn’s disease and ulcerative colitis
by: Neal Shahidi, et al.
Published: (2016-05-01)

Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A
by: Holger Schäffler, et al.
Published: (2017-12-01)

Good efficacy and safety of vedolizumab in Crohn’s disease and ulcerative colitis in a real-world scenario
by: Fabiana Zingone, et al.
Published: (2020-07-01)

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
by: Hiroyuki Okamoto, et al.
Published: (2021-01-01)

P571 Vedolizumab (VDZ) real-world outcomes in ulcerative colitis (UC)
by: Pulusu, S, et al.
Published: (2018)

Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK
by: Wilson MR, et al.
Published: (2017-10-01)

Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis
by: Haruka Miyazaki, et al.
Published: (2023-11-01)

Case report: Eosinophilic pneumonia associated with vedolizumab therapy in a patient with ulcerative colitis
by: Wanwan Zhu, et al.
Published: (2022-08-01)

Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
by: Friederike Fuchs, et al.
Published: (2017-07-01)

Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis
by: Keiichi Haga, et al.
Published: (2022-10-01)

Ulcerative colitis successfully treated with vedolizumab in the presence of comorbid opportunistic infections: a case report
by: Yusuke Oki, et al.
Published: (2023-05-01)

Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study
by: Choon Jin Ooi, et al.
Published: (2021-01-01)

Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis
by: Daisuke Saito, et al.
Published: (2021-09-01)

The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study
by: Byong Duk Ye, et al.
Published: (2021-07-01)

The safety profile of vedolizumab in ulcerative colitis and Crohn's disease: 4 years of global post-marketing data
by: Cohen, R, et al.
Published: (2019)

Confocal laser endomicroscopy as predictive biomarker of clinical and endoscopic efficacy of vedolizumab in ulcerative colitis: The DETECT study.
by: Lucille Quénéhervé, et al.
Published: (2024-01-01)

Confocal laser endomicroscopy as predictive biomarker of clinical and endoscopic efficacy of vedolizumab in ulcerative colitis: The DETECT study
by: Lucille Quénéhervé, et al.
Published: (2024-01-01)

Vedolizumab as Rescue Therapy in Carboplatin-Gemcitabine-Induced Triggered Acute Severe Ulcerative Colitis Flare-Up
by: Raffaele Pellegrino, et al.
Published: (2023-09-01)

Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China
by: Kaituo Huang, et al.
Published: (2023-05-01)

Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
by: Taku Kobayashi, et al.
Published: (2021-10-01)

Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis
by: Jun Miyoshi, et al.
Published: (2021-08-01)

Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study.
by: Satoshi Motoya, et al.
Published: (2019-01-01)

Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland
by: Pawel Petryszyn, et al.
Published: (2020-08-01)

Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials
by: Laurent Peyrin‐Biroulet, et al.
Published: (2024-03-01)

Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study
by: Jeong Yeon Kim, et al.
Published: (2020-03-01)

The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study
by: Chia-Jung Kuo, et al.
Published: (2022-09-01)

Human herpesvirus 8-associated colonic Kaposi’s sarcoma during vedolizumab treatment in ulcerative colitis: a case report and review of the literature
by: Valerio Papa, et al.
Published: (2020-03-01)

Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China
by: Ting Zhou, et al.
Published: (2021-08-01)

Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis
by: Ayaka Kaneoka, et al.
Published: (2022-02-01)

Intensification of maintenance therapy with infliximab in ulcerative colitis
by: Francesc Casellas

Knowledge, attitude and practices of patients receiving maintenance haemodialysis in Bloemfontein, South Africa
by: HC Spies, et al.
Published: (2021-07-01)

Vedolizumab Is Associated with Longer Drug Sustainability Compared to Infliximab in Moderate-to-Severe Ulcerative Colitis: Long-Term Real-World Cohort Data
by: Tom Konikoff, et al.
Published: (2023-07-01)

Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1
by: Loftus EV Jr, et al.
Published: (2020-06-01)

Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study
by: Clarissa Allner, et al.
Published: (2020-04-01)

What is the real-life maintenance mesalazine dose in ulcerative colitis?
by: Alicia Algaba, et al.

Review article: maintenance therapy in patients with ulcerative colitis.
by: Orchard, T, et al.
Published: (2006)